

Estrid Vilma Solyom Høgdall
Curriculum Vitae (2024)

Afdeling for Patologi

Herlev Hospital

Borgmester Ib Juuls Vej 73

2730 Herlev, Danmark

Phone: Work: +45 3868-9132; Mobil: +45 2681-0087

Publications: 442

Citations: 19.066

H-index: 71

Education:

- 2013: Thesis, University of Copenhagen. Dr. of Medical Science (DMSc) (dr. med) - *Prognostic value of selected biomarkers in ovarian cancer – Potential candidates for future personalized treatment?*
- 1999: Ph.d. (Med) - *Molecular biology investigations of bovine copper-dependent amine oxidase genes and preliminary expression studies of humane copper-dependent amine- and diamine oxidase genes.*
- 1991: Graduation as Master of Science of Pharmacy from University of Copenhagen.

Scientific employment:

- 2008- Professor, University of Copenhagen (May 2016), Head of Molecular Unit, Department of Pathology, Herlev University Hospital (2010) and National Director of Bio- and GenomBank, Denmark (RBGB) including 10 Nationwide biobanks among those Danish CancerBiobank (DCB, 2008) & Danish Reuma Biobank (2015), Danish BlooddonorBiobank (2017), Danish DiabetesBiobank (2018), Danish Covid19Biobank (D19B), Danish ScreeningBiobank DScB. Head of Biosek (2018)
- 2007-2008: Center project leader, Department of Pathology, Herlev Hospital
- 2000-2007: Clinical Senior Investigator Danish Cancer Society
- 1999-2004: Danish Cancer Society & State Serum Institute
- 1990-1999: Research fellow. Molecular Biology Department of Clinical Biochemistry, State Serum Institute
- 1989-1990: Research fellow Dept. Clinical Biochemistry, State Serum Institute
- 1986-1987: Research fellow, Smith's Pharmacy, Toronto, Canada

International positions

- 1995-2000:** Worked periodically as research fellow in London, UK, at St. Bartholomew's Hospital, in the Ovarian Cancer Screening Unit leaded by I. Jacobs, Prof., MD MRCOG. Research area: Development and validation of ovarian cancer tumor markers.
- Jan. – Apr. 2001:** Marie Curie individual fellowship: Individual Fellowships for researchers of any nationality to work outside their own country. The research fellowship was in Amsterdam, Holland, at Vrije University Medical Center, Dept. of Molecular Pathology/Molecular Laboratory Medicine leaded by Dr. A.J.C. van den Brule. Research area: Analyzing HPV subtypes in high-risk HPV Positive, cytologically normal women to estimate the absolute risk of cervical abnormalities over a period of 10 years.

Leadership and scientific experience

I am head of Molecular Unit, Department of Pathology, which I established in 2010. Furthermore, in the same period I have been responsible for the planning, initiation and management of DCB, first as a project leader later as Director. I am responsible for the biobank guideline description and programming of the database module. This leadership was a natural continuation of my position as head of the Gynecologic Cancer biobank group. The biobank infrastructure has now been extended to RBGB presently covering 10 Nationwide biobanks with expected extension. More biobanks are planned with me as Director, and the Secretary is placed at Department of Pathology, Herlev Hospital. The biobanks are founded by Danish Regions and hospitals. Furthermore, I am head of Biosek (2018) established to secure storage of biobank samples in RegH.

Career track records are documented in the areas: Molecular pathology, biobanking and various tumor profiling expression analyses. I have been primary investigator in several research studies. Special focus and experience in biomarkers of colorectal and ovarian tumors. Together with top international researchers I have established the

Ovarian Tumor Tissue Analysis (OTTA) Consortium, which consists of 30 studies including more than 8,000 ovarian cancer tissue samples.

In the COGCs project – 7.th framework program – I was coordinating the ovarian cancer activity in the Workpackage 6. In hematology an international collaboration with Sandeep Dave at Duke University, North Carolina, is started based on results established in a research study initiated from Department of Pathology, Herlev Hospital.

In addition, I attended the Global Excellence through Department of Gynaecology and Oncology at Rigshospitalet with MD Anderson, Professor R. Bast. In this collaboration Molecular Unit was partner and perform tissue micro arrays and different molecular analyses on sample material from both sites. The collaboration is still on-going. As a part of Mermaid III the Molecular Unit performs methylations studies, miR studies and global sequencing studies on tissue and blood samples from women diagnosed with ovarian tumors.

More than 220 publications within ovarian cancer. I have developed the Cph-Index, which is presently being validated in a study including patients from local hospitals and private gynecological doctors. Furthermore, development of methylation algorithms to be examined in cervical swabs to differentiate between malignant and benign ovarian disease. The two awards received is for development of a Point of Care for Cph-Index to be an easy platform for analyses and for development of an analyses for local HRD testing important for treatment decision of patients with ovarian cancer. More than 220 publications within ovarian cancer.

Awards and grants:

Ovacure Award 150.000 Euro (2022)

Oncomine Clinical Research Grant award 200.000 \$ (2022)

Mermaid III 19.583.000 kr. (2017-2022)

Yearly for RBGB approximately 15 million Dkr.

Earlier research fundings approximately 14 million Dkr.

Supervisor (completed): 19 PhD students and one doctoral thesis

Supervisor (ongoing): 8 PhD studies and 6 post Doc study

Patent: Proteomic Biomarkers for Overall and Progression-Free Survival in Ovarian Cancer Patients. U.S. Patent No.: 85567P (52903)